步行组合闭环大脑刺激可以改善帕金森步行障碍的步行动态:随机对照试验
Ippei Nojima1,2, Mitsuya Horiba2, Kento Sahashi2
1Physical Therapy, Shinshu University Graduate School of Health Sciences School of Health Sciences, Matsumoto, Nagano, Japan.
Journal of neurology, neurosurgery, and psychiatry
|June 9, 2023
概括
这项研究表明,步行结合的闭环跨电刺激 (tES) 显著改善了帕金森病患者的步行速度和步伐长度. 这种非侵入性神经调节为步态障碍提供了一个有前途的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 康复医学 康复医学 康复医学
背景情况:
- 步态障碍在帕金森病 (PD) 患者中显著影响日常生活活动.
- 目前对帕金森步行问题的治疗方法的有效性有限.
- 在之前的研究中,一种新的步态结合闭环跨电刺激 (tES) 方法显示出了前景.
研究的目的:
- 为了评估与帕金森症步态障碍患者的步态结合闭环tES的疗效.
- 确定tES是否可以改善PD患者的步态参数和主观症状.
- 探索tES作为一种非药物,非侵入性干预,用于PD相关的步态问题.
主要方法:
- 在一项随机对照试验中,23名患有帕金森症步态障碍的患者被录取.
- 参与者被分配到真实干预组或假控制组.
- 真正的干预涉及小脑的步态结合闭环振荡tES,与个人的步态节奏同步.
主要成果:
- 与假装组相比,实体tES组观察到步行速度和步伐长度的显著改善.
- 通过摇摆阶段时间测量的步行对称性在干预后显著增强.
- 接受真实tES的患者报告说,在步行时主观结感显著改善.
结论:
- 通过小脑的步行结合闭环tES有效改善帕金森症步行障碍.
- 这种干预可以通过调节负责步态节奏生成的大脑网络来起作用.
- 这种新的神经调节技术代表了在PD和相关疾病中恢复步行功能的潜在突破.
相关概念视频
01:24Parkinson's Disease: Treatment
305
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
305
01:15Parkinson's Disease: Overview
612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612